← Back to Screener
Aldeyra Therapeutics, Inc. (ALDX)
Price$1.66
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-78.93%
Price vs S&P 500 (4W)5.09%
VGM Score28.03
Market Capitalization$102.79M
All Metrics
Book Value / Share (Quarterly)$0.70
P/TBV (Annual)0.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.43
Price vs S&P 500 (YTD)-77.15%
EPS (TTM)$-0.46
10-Day Avg Trading Volume0.97M
EPS Excl Extra (TTM)$-0.46
EPS (Annual)$-0.56
ROI (Annual)-56.89%
Cash / Share (Quarterly)$1.08
ROA (Last FY)-46.97%
EBITD / Share (TTM)$-0.47
ROE (5Y Avg)-51.13%
Cash Flow / Share (Annual)$-0.55
P/B Ratio2.44x
P/B Ratio (Quarterly)2.41x
Net Income / Employee (Annual)$-4,230,800
Net Interest Coverage (TTM)-36.04x
ROA (TTM)-36.33%
EPS Incl Extra (Annual)$-0.56
Current Ratio (Annual)2.58x
Quick Ratio (Quarterly)2.71x
3-Month Avg Trading Volume2.39M
52-Week Price Return-23.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.08
52-Week High$6.17
EPS Excl Extra (Annual)$-0.56
Tangible BV CAGR (5Y)30.69%
26-Week Price Return-63.00%
Quick Ratio (Annual)2.56x
13-Week Price Return-68.18%
Total Debt / Equity (Annual)0.34x
Current Ratio (Quarterly)2.72x
Enterprise Value$53.08M
Book Value / Share Growth (5Y)-13.74%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.16
3-Month Return Std Dev178.04%
Net Income / Employee (TTM)$-3,421,200
ROE (Last FY)-76.49%
Net Interest Coverage (Annual)-60.78x
EPS Basic Excl Extra (Annual)$-0.56
Total Debt / Equity (Quarterly)0.36x
EPS Incl Extra (TTM)$-0.46
ROI (TTM)-43.47%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.58
Forward P/E24.57x
Price vs S&P 500 (52W)-51.45%
Year-to-Date Return-66.22%
5-Day Price Return12.90%
EPS Normalized (Annual)$-0.56
ROA (5Y Avg)-36.93%
Month-to-Date Return15.13%
Cash Flow / Share (TTM)$-0.77
EBITD / Share (Annual)$-0.58
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-42.59%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.46
P/TBV (Quarterly)1.21x
P/B Ratio (Annual)7.04x
Book Value / Share (Annual)$0.74
Price vs S&P 500 (13W)-77.93%
Beta1.21x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.34%
52-Week Low$1.07
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.06est. -0.10
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.25
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALDXAldeyra Therapeutics, Inc. | — | — | D | $1.66 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Aldeyra Therapeutics is a clinical-stage biotechnology company developing medicines for immune-mediated and metabolic diseases. Its lead candidate, Reproxalap, is in late-stage development for dry eye disease and allergic conjunctivitis. The company's pipeline also includes candidates targeting retinal diseases, autoimmune conditions, and cancer.